SCHEMBL47141

SCHEMBL47141

CCCc1noc(-c2cnc3nc(Nc4ccc(OC)cc4)n(CCCN4CCCCC4)c3n2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.40
HRH3 Q9Y5N1 3/20 0.39
NPC1 O15118 1/20 0.38
CNR2 P34972 2/20 0.36
BCHE P06276 1/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.35
TERT O14746 1/20 0.34
EGFR P00533 1/20 0.34
HRH2 P25021 1/20 0.34
TLR9 Q9NR96 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
ABL1 P00519 1/20 0.33
NTRK1 P04629 1/20 0.33
YES1 P07947 1/20 0.33
PIM1 P11309 1/20 0.33
MAPK1 P28482 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL47099 0.88 MC4R (0.46) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47144 0.87 MC4R (0.42) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47158 0.86 HRH3 (0.49) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47147 0.85 MC4R (0.44) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47148 0.85 MC4R (0.44) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47130 0.79 MC4R (0.46) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47159 0.77 MC4R (0.46) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47260 0.76 MC4R (0.48) MC4RHRH3NPC1CNR2BCHE
SCHEMBL47143 0.75 MC4R (0.46) MC4RHRH3NPC1CNR2BCHE
SCHEMBL46851 0.74 MC4R (0.54) MC4RCNR2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165426-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS Université de Montréal (CA) 2013-06-27 US disclosed
US-20130165426-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS Université de Montréal (CA) 2013-06-27 US disclosed
WO-2012003576-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS Université de Montréal (CA) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165426-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS MC4R, MC5R, MC1R MC4R 1/4885HRH3 88/4885NPC1 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.